A close reading of the published clinical data on Potassium Azeloyl Diglycinate. The dosages, the co-actives, and the measured outcomes on human skin.
Right now, your skin is losing a fight on four fronts. UV radiation is triggering overactive melanocytes to dump melanin into patches that darken every week you ignore them. Microscopic Demodex mites inside your follicles are catalyzing a protease cascade that floods your cheeks with the inflammatory peptide LL-37, turning mild redness into chronic, burning rosacea. Excess dihydrotestosterone is forcing your sebaceous glands to overproduce oil, clogging pores from the inside. And every harsh product you apply to fix any of this is stripping the lipid barrier that holds moisture in, so your skin dries out, cracks, and inflames even faster.
This is a four-system failure. And every conventional treatment addresses one problem while making another worse. High-strength azelaic acid (15 to 20%) inhibits tyrosinase to slow pigmentation and kills C. acnes to clear breakouts, but its low pH of 4.0 to 5.0 can compromise the stratum corneum and destabilize co-formulated actives like retinol. Retinoids suppress sebum but cause peeling and photosensitivity. Benzoyl peroxide nukes bacteria but induces xerosis. Every standard active demands you trade one form of damage for another.
Potassium Azeloyl Diglycinate changes that equation. The molecule is azelaic acid’s nine-carbon backbone bonded to two molecules of glycine and neutralized with potassium. That single structural change transforms the compound from a lipophilic, insoluble irritant into a water-soluble, pH-neutral amphiphile that crosses the stratum corneum at a fraction of the concentration. As a derivative of azelaic acid, PAD is expected to retain the parent molecule’s pharmacological properties: competitive tyrosinase inhibition, KLK5 protease suppression, downregulation of IL-1α and IL-6, reactive oxygen species scavenging, and 5-alpha reductase inhibition. The bonded glycine additionally deposits free glycine into the Natural Moisturizing Factor of corneocytes. Critically, PAD’s neutral working pH makes it fully compatible with encapsulated retinol — a combination that traditional azelaic acid’s acidic pH makes inherently unstable. The clinical trials described below measured the downstream outcomes of these pathways, though the specific molecular mechanisms were not directly assayed in vivo at the 5% PAD dosage.
PAD is expected to preserve the pharmacological properties of azelaic acid (tyrosinase inhibition, KLK5 suppression, bacteriostasis, ROS scavenging, 5-alpha reductase inhibition) while its neutral pH and water solubility eliminate the barrier disruption and formulation incompatibilities associated with the parent compound. This is what makes PAD uniquely suited to co-formulation with retinol — the one combination traditional azelaic acid cannot reliably achieve. The result in clinical trials: meaningful outcomes at one-quarter the dose, in combination formulations with excellent tolerability.
Forty-two rosacea patients were randomized to receive either a 5% PAD + 1% hydroxypropyl chitosan (HPCH) cream or a matched placebo, applied twice daily for 28 days with a 2-week follow-up. Redness was measured objectively using a Mexameter, not self-reporting. The results were decisive.
The composite erythema index dropped significantly at every facial site measured: forehead down 37.0 points (p=0.009), right cheek down 36.1 (p=0.010), left cheek down 38.8 (p=0.002), and chin down 53.3 (p=0.002). By the day 42 follow-up, clinical inspection confirmed that erythema had visually disappeared in 95% of treated subjects based on a 4-point clinical grading scale.
| Forehead erythema reduction | p = 0.009 |
| Right cheek reduction | p = 0.010 |
| Left cheek reduction | p = 0.002 |
| Chin reduction | p = 0.002 |
| Hydration increase (forehead, day 14) | p = 0.030 |
| Hydration increase (forehead, day 28) | p = 0.020 |
Simultaneously, stratum corneum hydration increased significantly on the forehead: +4.9 at day 14 (p=0.030) and +5.7 at day 28 (p=0.020). The authors noted that increased hydration was observed in both the active and placebo groups, attributable to the moisturizing base cream. The significance on the forehead in the active group was modest and should not be interpreted as a unique PAD-driven hydration effect. However, the erythema reduction was decisively in favor of the active formulation. The tolerability profile was flawless: exactly zero adverse reactions were documented across the entire trial in both groups.
For context, standard 15% azelaic acid can cause transient stinging and burning upon application during the first weeks of use. This PAD + HPCH formulation achieved erythema improvement at one-third the concentration without that trade-off.
Sixty-seven Thai adults with epidermal melasma were randomized to receive either a PAD + niacinamide + tranexamic acid emulsion or an emulsion-based control, applied twice daily for 8 weeks with mandatory SPF 30. This was a multi-active formulation, and the individual contribution of each ingredient cannot be isolated from the combined results.
The Relative Melanin Value (the absolute melanin gap between darkened and normal skin) showed a statistically significant reduction versus control by week 6 (p=0.005 ITT, p=0.006 on-treatment). MASI scores, the clinical gold standard for melasma severity, improved significantly versus control at week 4 in the on-treatment population (p=0.005) and at week 8 in the primary intent-to-treat population (p=0.027).
| Relative Melanin Value (ITT, week 6) | p = 0.005 |
| Relative Melanin Value (OT, week 6) | p = 0.006 |
| MASI score improvement (OT, week 4) | p = 0.005 |
| MASI score improvement (ITT, week 8) | p = 0.027 |
The tolerability data is what separates this trial from hydroquinone and high-dose azelaic acid studies. Adverse events (mild erythema, minor scaling) occurred in 12% of the active group versus 15% of the emulsion-based control group. The difference was not statistically significant, meaning the active formulation’s irritation profile was comparable to its control vehicle.
This trial used three active ingredients working through distinct biological pathways: PAD inhibits tyrosinase to slow melanin production, niacinamide blocks melanosome transfer to surrounding keratinocytes, and tranexamic acid interferes with the plasmin pathway implicated in UV-induced pigmentation. PAD’s water solubility and neutral pH allowed all three to be combined in a single stable emulsion. Traditional azelaic acid’s low pH can create formulation challenges when combined with pH-sensitive co-actives, though careful buffering can address this in some formulations.
Thirty-seven Caucasian adults with erythemato-telangiectatic rosacea and intense chronic burning and stinging were enrolled across multiple clinical sites. They applied 5% PAD + 1% hydroxypropyl chitosan cream twice daily for 12 weeks. Of the 37 enrolled, 30 (81.1%) completed the study and were considered evaluable. This was an open-label study with no control group, meaning results should be interpreted with more caution than the double-blind RCTs above.
Neurogenic inflammation was quantified using a 4-point clinical scale. Baseline total symptom score across the evaluable cohort was 66 points (mean 2.2 per patient). By week 12, the total score dropped to 37 points (mean 1.2), representing a 56.1% reduction in stinging and burning.
Standard azelaic acid can induce transient burning upon application. Patients sometimes endure the very symptom their rosacea produces just to use the treatment. This trial measured the inverse: the PAD + HPCH formulation actively reduced the burning sensation caused by the disease itself. Over 12 weeks of twice-daily chronic use, physicians documented zero side effects among the evaluable patients.
This is the trial that reframes PAD-based formulations as a neurogenic intervention, not just a cosmetic active. The combination does not merely avoid causing pain. It treats pain.
Conventional dermatology follows a simple assumption: higher concentration equals stronger result. Azelaic acid operates under this logic. At 10%, it is sub-therapeutic. At 15%, it reaches clinical threshold. At 20%, it achieves its maximum measurable benefit, but inflicts significant barrier damage. The dose-response curve is steep, narrow, and punishing.
PAD breaks that curve entirely. In the Maramaldi in vivo evaluations (manufacturer data published in Cosmetics & Toiletries, 2002 — note: industry trade publication, not a peer-reviewed clinical trial), a 3% aqueous PAD solution applied for just 21 days increased skin luminance (L*) by up to 5.4%, reduced redness (a*) by 12.2%, cut T-zone sebum by 29.4%, and simultaneously increased stratum corneum moisture by 12.7% on the forehead and 8.2% on the cheeks. Measurable depigmentation, sebum control, and hydration gains at 3%.
The Berardesca and Veraldi trials both used 5% (in combination with hydroxypropyl chitosan), achieving 95% erythema clearance and a 56.1% burn reduction respectively. No trial tested concentrations above 5% because the clinical endpoints were already met. Pushing beyond 5% would not improve outcomes; it would only increase raw material cost and move the pH away from the neutral window that keeps PAD tolerable and retinol-compatible.
Concentration is not the bottleneck. Bioavailability is. Traditional azelaic acid requires 15 to 20% because the molecule has poor solubility. PAD’s amphiphilic structure, driven by the bonded glycine, improves its aqueous solubility and may improve its ability to cross the stratum corneum. No head-to-head comparative penetration study has been published, but the clinical data converges on 5% as the effective dose in the formulations tested. Going higher has not been demonstrated to improve outcomes.
“PAD-based formulations achieved meaningful clinical outcomes at a fraction of the concentration required by traditional azelaic acid, with a significantly improved tolerability profile.”
Summary of cited clinical dataVector ONE
SATURATE Vector ONE is the first formulation to combine Potassium Azeloyl Diglycinate with encapsulated retinol in a single product. Traditional azelaic acid’s low pH degrades retinol on contact, making co-formulation impossible without compromising one or both actives. PAD’s neutral working pH solves this entirely. The formulation carries PAD at 8%, exceeding the 5% concentration used in the cited clinical trials. While no published trial has tested above 5%, the 8% dose provides a margin above the proven threshold. The vehicle is a lightweight oil-in-water emulsion built on a Cetearyl Olivate and Sorbitan Olivate emulsifier system, reinforced with squalane, shea butter, and hydrogenated lecithin to deliver lipid-phase actives without occluding pores.
This is not a reformulation of azelaic acid in a nicer bottle. It is a structurally distinct molecule with a distinct solubility and tolerability profile, paired for the first time with encapsulated retinol in a single nightly application. The clinical data supports PAD’s efficacy in combination formulations. Vector ONE puts that science to work.
[2] Berardesca E, Iorizzo M, Abril E, et al. “Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea.” J Cosmet Dermatol, 2012; 11(1):37-41. (Double-blind RCT; includes co-authors from Sinerga and Polichem.)
[3] Viyoch J, Tengamnuay I, Phetdee K, et al. “Effects of Trans-4-(Aminomethyl) Cyclohexanecarboxylic Acid/Potassium Azeloyl Diglycinate/Niacinamide Topical Emulsion in Thai Adults With Melasma.” Curr Ther Res Clin Exp, 2010; 71(6):345-359. (Double-blind RCT; multi-active formulation.)
[4] Veraldi S, Raia DD, Schianchi R, et al. “Treatment of symptoms of erythemato-telangiectatic rosacea with topical potassium azeloyl diglycinate and hydroxypropyl chitosan.” J Dermatolog Treat, 2015; 26(2):191-192. (Sponsor-free, multicenter, open-label study; no control group.)
[5] Kostrzebska A, et al. “Synergy of Tetracyclines and Potassium Azeloyl Diglycinate (Azeloglycine) in Hydrogels: Evaluation of Stability, Antimicrobial Activity, and Physicochemical Properties.” Int J Mol Sci, 2025; 26(11):5239.
[6] Aggregate data: Maramaldi in vivo evaluations (sebum, hydration, luminance, erythema parameters), 2002. (Industry data; not independently peer-reviewed.)
